Butyrylcholinesterase activity and mortality risk in hemodialysis patients: Comparison to hsCRP and albumin

Clinical Biochemistry

Volumn 42, Issue 1-2, 2009, Pages 22-26

  Stojanov, Marina D ^a   Jovičić, Dušanka M ^b   Djurić, Stevan P ^b   Konjević, Marija M ^b   Todorović, Zoran M ^a   Prostran, Milica Š ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b GENERAL HOSPITAL   (Serbia)

Author keywords

Albumin; Butyrylcholinesterase; End stage renal disease; Hemodialysis; High sensitivity C reactive protein

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CHOLINESTERASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH SENSITIVITY C REACTIVE PROTEIN; NITRATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; KIDNEY POLYCYSTIC DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROSCLEROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; BUTYRYLCHOLINESTERASE; C-REACTIVE PROTEIN; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; SERUM ALBUMIN;

EID: 57649115640     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.10.010     Document Type: Article

References (33)

1. USRDS. Annual Data Report (2007), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, USA
2. USRDS. Annual Data Report (2004), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, USA
3. Hercog C.A., Ma J.Z., and Collings A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N. Engl. J. Med. (1998) 779-805
4. Apple F.S., Murakami M.M., Pearce L.A., and Herzog C.A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106 (2002) 2941-2945
5. Korevaar J.C., Van Manen J.G., Dekker F.W., De Eaart D.R., Boeschoten E.W., Krediet R.T., and the Necosad Study Group. Effect of an Increase in C-reactive protein level during a hemodialysis session on mortality. J. Am. Soc. Nephrol. 15 (2005) 2916-2922
6. Conway B., McLaughlin M., Sharpe P., and Harty J. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic harmodialysis. Nephrol. Dial. Transplant. 20 (2005) 2759-2764
7. Yeun J.Y., Levine R.A., Mantadilok V., and Kaysen G. C-reactive protein predicts all-cause death and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 35 (2000) 469-476
8. Madsen L.H., Ladefoged S., Corell P., Schou M., Hikdebrant P.R., and Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 71 (2007) 548-554
9. Iseki K., Kawasoe N., and Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int. 44 (1993) 115-119
10. Quresci A.R., Alvestrand A., Danielsson A., et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J. Am. Soc. Nephrol. 13 (2002) S28-S36
11. Darvesh S., Hopkins D.A., and Geula C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 4 (2003) 131-138
12. Whittaker M. Cholinesterase. In: Beckman L. (Ed). Monograph in Human Genetics 11 (1986), Karger, New York 134pp
13. De la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33 (2002) 1152-1162
14. Alcantara V.M., Chautard-Freire-Maia E.A., Scartezini M., Cerci M.S., Braun-Prado K., and Picheth G. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand. J. Lab. Invest. 62 (2002) 399-404
15. Magarian E.O., and Dietz A.J. Correlation of cholinesterase with serum lipids and lipoproteins. J. Clin. Pharmacol. 27 (1987) 819-820
16. Berry W.T.C., Cowin P.J., and Davies D.R. A relationship between body fat and plasma pseudo-cholinesterase. Br. J. Nutr. 8 (1954) 79-82
17. Garcia S.C., Wyse A.T.S., Valentini J., Roehrs M., Moro A.M., Paniz C., et al. Butyrylcholinesterase activity is reduced in hemodialysis patients: is there association with hyperhomocysteinemia and/or oxidative stress?. Clin. Biochem. 41 (2008) 474-479
18. Klein J.P., and Moeschberger M.L. Survival Analysis: Techniques for Censored and Truncated Data (1997), Springer, New York, NY
19. Sonician M., and Parissis J.T. Cardiovascular diseases and hemodialysis: novel strategies for diagnosis, prevention and treatment. Hellenic J. Cardiol. 44 (2003) 206-217
20. Zimmermann J., Herrlinger S., Pruy A., et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 55 (1999) 648-658
21. Yeun J.Y., Levine R.A., Mantadilok V., et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 35 (2000) 469-476
22. De Filippi C., Wasserman S., Rosanio S., et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290 (2003) 353-359
23. Calderon-Margalit R., Adler B., Abramson J.H., Gofin J., and Kark J.D. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin. Chem. 52 (2006) 845-852
24. Masson P. A naturally occurring molecular form of human plasma cholinesterase is an albumin conjugate. Biochim. Biophys. Acta 998 (1989) 258-266
25. Maekawa M., Sudo K., Dey D.C., Ishikawa J., Izumi M., Kotani K., et al. Genetic mutations of butyrylcholinesterase identified from phenotypic abnormalities in Japan. Clin. Chem. 43 (1977) 924-929
26. Kalantar-Zadeh K., and Kopple J.D. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am. J. Kidney Dis. 38 (2001) 1343-1350
27. Stenvinkel P., Heimburger O., Lindholm B., Kaysen G.A., and Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol. Dial. Transplant. 15 (2000) 953-960
28. Wanner C., Zimmermann J., Schwedler S., and Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int 61 Suppl 80 (2002) 99-102
29. Steck E.L., Matee C., Vieira P.S., Rombaldi F., Clovis M., and Wannmacher D. Reduction of Na(+), K(+), ATPase activity in hippocampus of rats subjected to chemically induced hyperhomocysteinemia. Neurochem Res. 27 (2002) 1592-1598
30. Scherer B.S., Stefanello F.M., Mattos C., Netto C.A., and Ways T.S. Homocysteine reduces cholinesterase activity in rat and human serum. Int. J. Dev. Neurosci. 25 (2007) 201-205
31. Stefanello F.M., Franzon R., Tagliari B., Wannmacher D., Wajner M., and Wyse A.T. Reduction of butyrylcholinesterase activity in rat serum subjected to hyperhomocysteinemia. Met. Brain Dis. 20 (2005) 97-103
32. Kalman J., Juhasy A., Rakonczay Z., Abraham G., Zana M., Boda K., et al. Increased serum butyrylcholinesterase activity in rat serum subjected to hyperhomocysteinemia. Metab. Brain Dis. 20 (2005) 97-103
33. Rustemeijer C., Schouten J.A., Voerman H.J., Beynen A.C., Donker A.J., and Heine R.J. Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in type II diabetes mellitus?. Clin Sci. 101 (2001) 29-35